Binding mode of VEGF receptor tyrosine kinase KDR (VEGFR-2) inhibitors.

被引：0

作者：

McGaughey, G ^{[1
]}

Bilodeau, M ^{[1
]}

Coll, K ^{[1
]}

Gibbs, J ^{[1
]}

Hartman, G ^{[1
]}

Huckle, W ^{[1
]}

Hungate, R ^{[1
]}

Johnson, A ^{[1
]}

Kendall, R ^{[1
]}

Koester, T ^{[1
]}

Kohl, N ^{[1
]}

Mao, XZ ^{[1
]}

McFall, R ^{[1
]}

Pan, BS ^{[1
]}

Rickert, K ^{[1
]}

Rodman, L ^{[1
]}

Rutledge, R ^{[1
]}

Thomas, K ^{[1
]}

机构：

[1] Merck Res Labs, W Point, PA 19486 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2002年 / 224卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

088-COMP

引用

页码：U482 / U482

页数：1

共 50 条

[1] Development and in vivo evaluation of novel inhibitors of the VEGF receptor tyrosine kinase KDR (VEGFR-2)
Bilodeau, MT
Coll, KE
Cunningham, AM
Hartman, GD
Huckle, WR
Hungate, RW
Kendall, RL
Koester, TJ
Rodman, LD
McFall, RC
Mao, XZ
Rutledge, RE
Thomas, KA
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : B142 - B142
[2] Development of thienopyridines as VEGFR-2 kinase inhibitors.
Munchhof, MJ
Adams, MA
Atherton, JA
Beebe, JS
Casavant, JC
Cooper, BC
Doty, JD
Emerson, EE
Foster, BF
Gant, TG
Garshasb, SG
Goodwin, PG
Harriman, SH
Higdon, CH
Hillerman, SH
Interi, CI
Jani, JJ
Knauth, LK
Marx, MM
Natarajan, VN
Noe, MN
Rossi, AR
Savage, DS
Shaeffer, TS
Smolarek, TS
Snow, SS
Sobolov, SS
Soderstrom, ES
Sun, JS
Turncliff, RT
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U197 - U197
[3] Discovery, synthesis, SAR, and in vitro/in vivo characterization of a novel quinolinone class of VEGFR-2 (KDR) kinase inhibitors.
Fraley, ME
Antanavage, J
Arrington, KL
Ciecko, PA
Coll, KE
Gibbs, JB
Hambaugh, SR
Hartman, GD
Heimbrook, DC
Hoffman, WF
Hungate, RW
Kohl, NE
Mao, XZ
McFall, RC
Rands, E
Rickert, K
Sepp-Lorenzino, L
Shipman, JM
Tebben, AJ
Thomas, KA
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U44 - U45
[4] Development and strategies of VEGFR-2/KDR inhibitors
Huang, Lingyi
Huang, Zhengui
Bai, Zhigiang
Xie, Rui
Sun, Liping
Lin, Kejiang
[J]. FUTURE MEDICINAL CHEMISTRY, 2012, 4 (14) : 1839 - 1852
[5] De novo Design of Indole Derivatives as VEGFR-2 Tyrosine Kinase Inhibitors
Kang Congmin
Zhao Xuhao
Yu Yuqi
Lu Yingtao
[J]. CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE, 2014, 35 (03): : 550 - 554
[6] 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors
Tripathy, Rabindranath
Ghose, Arup
Singh, Jasbir
Bacon, Edward R.
Angeles, Thelma S.
Yang, Shi X.
Albom, Mark S.
Aimone, Lisa D.
Herman, Joseph L.
Mallamo, John P.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (06) : 1793 - 1798
[7] Design, synthesis, and evaluation of OSI-930 analogs as dual c-Kit and KDR (VEGFR-2) tyrosine kinase inhibitors
Patel, Jay
Korlipara, Vijaya L.
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
[8] A novel cytoplasmic mechanism for the regulation of receptor tyrosine kinase, VEGFR-2, dimerization
Sivendran, Renuka
Li, Hongmei
Seo, Dong-wan
Stetler-Stevenson, William
[J]. CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (07) : 884 - 884
[9] A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
Joukov, V
Pajusola, K
Kaipainen, A
Chilov, D
Lahtinen, I
Kukk, E
Saksela, O
Kalkkinen, N
Alitalo, K
[J]. EMBO JOURNAL, 1996, 15 (02): : 290 - 298
[10] Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors
Garofalo, Antonio
Goossens, Laurence
Six, Perrine
Lemoine, Amelie
Ravez, Severine
Farce, Amaury
Depreux, Patrick
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (07) : 2106 - 2112

← 1 2 3 4 5 →